A Different Perspective with Pedro Gonzalez de Cosio: How Pharmakon Is Transforming Life Sciences Financing

This week Nick talks to Pedro Gonzalez de CosioPedro Gonzalez de Cosio is the Chief Executive Officer and co-founder of Pharmakon. Before co-founding the firm, he spent 14 years in structured finance, holding senior roles at Deutsche Bank and JPMorgan in New York. There, he specialized in structuring complex collateralized financing and derivative transactions for U.S. and international clients, including several years focused on the biotechnology and pharmaceutical sectors. Pedro is also the Investment Manager at BioPharma Credit PLC. Nick and Pedro discuss Pharmakon’s approach to providing non-dilutive debt financing to life sciences companies, how the firm supports biotech businesses through key growth stages, and what differentiates its investment strategy. They also explore successful investments, the role of non-dilutive capital in funding innovation and acquisitions, the competitive landscape for biotech financing, differences between U.S. and European capital markets, and emerging healthcare trends, including orphan diseases, oncology, GLP-1 therapies, AI in drug discovery, and the future of cancer treatment. Pedro's Book ChoicesThe Godfather by Mario Puzo The Emperor of All Maladies by Siddhartha Mukherjee Pedro's Music ChoicesPiano Man by Billy JoelPagliacci OperaThis content is issued by Zeus Capital Limited (“Zeus”) (Incorporated in England & Wales No. 4417845), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (“FCA”) for designated investment business, (Reg No. 224621) and is a member firm of the London Stock Exchange. This content is for information purposes only and neither the information contained, nor the opinions expressed within, constitute or are to be construed as an offer or a solicitation of an offer to buy or sell the securities or other instruments mentioned in it. Zeus shall not be liable for any direct or indirect damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only.